KB
TRIB

Kimelman & Baird’s Trinity Biotech TRIB Stock Holding History

Kimelman & Baird’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-716
Closed -$1.42M – 123
2016
Q3 		$1.42M Sell
716
-4
-0.6% -$7.47K 0.25% 55
2016
Q2 		$1.22M Sell
720
-9
-1% -$15.2K 0.22% 55
2016
Q1 		$1.27M Buy
729
+4
+0.6% +$6.37K 0.24% 56
2015
Q4 		$1.28M Buy
+725
New +$1.28M 0.24% 61
2015
Q2 		$3.82M Buy
1,410
+219
+18% +$569K 0.65% 45
2015
Q1 		$3.44M Buy
1,191
+292
+32% +$810K 0.63% 47
2014
Q4 		$2.36M Sell
899
-296
-25% -$765K 0.43% 51
2014
Q3 		$3.28M Sell
1,195
-26
-2% -$84.5K 0.62% 46
2014
Q2 		$4.22M Buy
1,221
+58
+5% +$206K 0.74% 42
2014
Q1 		$4.23M Buy
1,163
+746
+179% +$2.93M 0.79% 37
2013
Q4 		$1.57M Buy
+417
New +$1.5M 0.3% 61

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Kimelman & Baird's TRIB Position: Q4 2016 in Review

Kimelman & Baird sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 716 shares — an estimated $1.42M sold.

Kimelman & Baird first reported a position in TRIB in Q4 2013 and held it in 11 quarters. The position peaked at $4.23M in Q1 2014. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Kimelman & Baird reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Kimelman & Baird sold 716 Trinity Biotech shares in Q4 2016, an estimated $1.42M.
  • Kimelman & Baird first reported a position in Trinity Biotech in Q4 2013 and held it in 11 quarters.
  • Kimelman & Baird's Trinity Biotech position peaked at $4.23M in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Kimelman & Baird's 13F filing for Q4 2016, filed 10 Apr 2017.